In this video, Dr. Cross, a member of the IBD Journal editorial board, previews the Editor's Focus session that will feature gastroenterology professionals discussing the most important pieces from the major peer-reviewed journals in the field published this year.

Raymond Cross, MD, is a professor of medicine and director of the IBD Program at the University of Maryland in Baltimore.

TRANSCRIPT

Good morning. I'm Raymond Cross from the University of Maryland School of Medicine. I'm Professor of Medicine and Director of the IBD Program. I wanted to tell you about an upcoming session called "Editor's Focus." If you've had trouble keeping up with your reading this year and you were going to attend 1 session at Advances, this would be the one to attend.

The various associate editors or editors for Gastroenterology, Clinical Gastroenterology and Hepatology, The American Journal of Gastroenterology, and the IBD Journal are going to present what they consider to be the best of those respective journals in IBD for 2020.

I'm going to be presenting the section on the IBD Journal. Over the course of 15 minutes, we're going to give the highlights of a number of studies, studies focusing on cost of IBD care and the impact of high-deductible health plans, the role of a Mediterranean diet on improving control of disease, biomarkers such as peripheral blood eosinophilia, special subgroups of patients with IBD such as those with PSC-UC.

We're going to answer the question, is aspirin use safe for your patients with cardiac comorbidities? A question that comes up in clinical practice is, does infliximab or other anti-TNFs result in weight gain? We're going to analyze that.

Then we're going to spend a little bit of time talking about colorectal cancer, risk factors for colorectal cancer as well as the impact on medical therapy on development of colorectal cancer over time.

Then, as a bonus to our session, Uma Mahadevan is going to give the results of the PIANO registry. For those of you not familiar, PIANO is a large national registry of pregnant women with IBD evaluating the safety of our various therapies. She's going to share the results.

This is a must-watch virtual training. I hope to see you there.